1. Ruiz-Fernández de Córdoba, Borja, Martínez-Monge, Rafael, Lecanda, Fernando. . ENPP1 Immunobiology as a Therapeutic Target. In Clinical cancer research : an official journal of the American Association for Cancer Research, 29, 2184-2193. doi:10.1158/1078-0432.CCR-22-1681. https://pubmed.ncbi.nlm.nih.gov/36719675/
2. Hunter, Francis W, Barker, Hilary R, Lipert, Barbara, Sotiriou, Christos, Jamieson, Stephen M F. 2019. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. In British journal of cancer, 122, 603-612. doi:10.1038/s41416-019-0635-y. https://pubmed.ncbi.nlm.nih.gov/31839676/
3. Najjar, Mariana K, Manore, Sara G, Regua, Angelina T, Lo, Hui-Wen. 2022. Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer. In Genes, 13, . doi:10.3390/genes13112065. https://pubmed.ncbi.nlm.nih.gov/36360302/
4. Buettner, Ralf, Nguyen, Le Xuan Truong, Morales, Corey, Marcucci, Guido, Rosen, Steven T. 2021. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine. In Journal of hematology & oncology, 14, 70. doi:10.1186/s13045-021-01076-4. https://pubmed.ncbi.nlm.nih.gov/33902674/
智鼠故事 
